Navigation Links
Arbitration Panel Finds in Favor of Tennessee Victim of Mariner Nursing Home Negligence
Date:9/3/2009

el rendered its award, finding unanimously for the Plaintiff on the ordinary negligence, medical malpractice and TAPA survival claims. The damage awards (items X and XII in the link) were determined by a majority of the panel. A copy of the Arbitration Panel's findings is linked here: (http://www.marksfirm.com/pdf/media%20cover/TN_tapa_malpractice.pdf)

The amounts awarded, totaling $2,773,396.32 were as follows:

  • TAPA violations -- $250,000
  • Attorneys fees for intentional, malicious or fraudulent misconduct resulting in a TAPA violation -- $400,000
  • Medical malpractice -- $626,396.32
  • Punitive damages -- $1,500,000

Marks Balette & Giessel is a nationally recognized litigation firm focused on the trial of complex, high-stakes civil cases. The firm's unparalleled commitment, dedication to excellence, and passion for jury trials have resulted in some of the largest verdicts and settlements in the country. For more information about this firm and their results, please see their website at http://www.marksfirm.com/.


'/>"/>
SOURCE Marks Balette & Giessel
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
2. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
3. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
4. Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement
5. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
6. Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied
7. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
8. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
11. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 1Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 2Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 3Clues to Hypertension in Kids May Be Seen in Bones 59798 1Clues to Hypertension in Kids May Be Seen in Bones 59798 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 1Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 3
Other Medicine Technology:Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6